Sofosbuvir subsidised in Australia for hepatitisC

Sofosbuvir subsidised in Australia for hepatitisC PharmacoEconomics & Outcomes News 784, p37 - 12 Aug 2017 Sofosbuvir subsidised in Australia for hepatitis C Sofosbuvir (Epclusa) will be subsidised in Australia for the treatment of hepatitis C from 1 August 2017, via the Pharmaceutical Benefits Scheme (PBS). Sofosbuvir is the first of the new direct acting antivirals that can be used in the treatment of patients with any genotype of hepatitis and has an expected success rate of 90%. Up to 200 000 Australians are infected with hepatitis C, with approximately 800 people dying from the infection each year. The newly announced government funding will reduce the treatment cost to the patient to a maximum of $A38.80 per month, with the concessional price being just $6.30, compared with unsubsidised costs of over $20 000 per treatment. "Eliminating hepatitis C from Australia will take a coordinated effort from GPs, specialists, nurses, patients and the Government", commented Minister for Health, the Hon. Greg Hunt MP. "Today is World Hepatitis Day and I want to reiterate the Government’s commitment to eliminate hepatitis C in Australia by 2030". Over 42 000 Australians have benefited from PBS- subsidised medicine for chronic hepatitis C since Australia became one of the first countries in the world to subsidise new medicines for all adults with chronic infection. As well as allocating over $1 billion for these new medicines over the next five years through the PBS, the Australian government is providing education to health professionals about hepatitis B and C, as well as funding hepatitis B vaccination for all infants. Additionally, free catch-up vaccines became available on 1 July 2017 for all refugees, humanitarian entrants and 10 to 19-year-olds through the National Immunisation Program. Hon Greg Hunt MP, Minister for Health, Minister for Sport. New drug to help over 200,000 Australians. Internet Document : 28 Jul 2017. Available from: URL: http://www.health.gov.au/internet/ministers/publishing.nsf/Content/health-mediarel- yr2017-hunt072.htm 803262349 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Sofosbuvir subsidised in Australia for hepatitisC

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/sofosbuvir-subsidised-in-australia-for-hepatitisc-JM49BaSXX2
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4248-5
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics & Outcomes News 784, p37 - 12 Aug 2017 Sofosbuvir subsidised in Australia for hepatitis C Sofosbuvir (Epclusa) will be subsidised in Australia for the treatment of hepatitis C from 1 August 2017, via the Pharmaceutical Benefits Scheme (PBS). Sofosbuvir is the first of the new direct acting antivirals that can be used in the treatment of patients with any genotype of hepatitis and has an expected success rate of 90%. Up to 200 000 Australians are infected with hepatitis C, with approximately 800 people dying from the infection each year. The newly announced government funding will reduce the treatment cost to the patient to a maximum of $A38.80 per month, with the concessional price being just $6.30, compared with unsubsidised costs of over $20 000 per treatment. "Eliminating hepatitis C from Australia will take a coordinated effort from GPs, specialists, nurses, patients and the Government", commented Minister for Health, the Hon. Greg Hunt MP. "Today is World Hepatitis Day and I want to reiterate the Government’s commitment to eliminate hepatitis C in Australia by 2030". Over 42 000 Australians have benefited from PBS- subsidised medicine for chronic hepatitis C since Australia became one of the first countries in the world to subsidise new medicines for all adults with chronic infection. As well as allocating over $1 billion for these new medicines over the next five years through the PBS, the Australian government is providing education to health professionals about hepatitis B and C, as well as funding hepatitis B vaccination for all infants. Additionally, free catch-up vaccines became available on 1 July 2017 for all refugees, humanitarian entrants and 10 to 19-year-olds through the National Immunisation Program. Hon Greg Hunt MP, Minister for Health, Minister for Sport. New drug to help over 200,000 Australians. Internet Document : 28 Jul 2017. Available from: URL: http://www.health.gov.au/internet/ministers/publishing.nsf/Content/health-mediarel- yr2017-hunt072.htm 803262349 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784

Journal

PharmacoEconomics & Outcomes NewsSpringer Journals

Published: Aug 12, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off